Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
This article was originally published in The Gray Sheet
Executive Summary
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers